难治性-话题@MedSci

#难治性#

683篇内容 | 2679人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528462, encodeId=62d4152846246, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Leukemia：复发/难治性MM治疗进展：新药、单克隆抗体及免疫治疗, objectType=article, longId=136132, objectId=a8de13613289, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de13613289, replyNumber=0, likeNumber=73, createdTime=2018-04-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de13613289, moduleTitle=Leukemia：复发/难治性MM治疗进展：新药、单克隆抗体及免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8de13613289)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528461, encodeId=e1ea1528461e4, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Prostate：在非转移性去势难治性前列腺癌患者中，早期雄激素受体靶向药物治疗能够提高总生存, objectType=article, longId=136082, objectId=990613608223, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=990613608223, replyNumber=0, likeNumber=74, createdTime=2018-04-22, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=990613608223, moduleTitle=Prostate：在非转移性去势难治性前列腺癌患者中，早期雄激素受体靶向药物治疗能够提高总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=990613608223)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528460, encodeId=bc0515284605c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=PLoS One：转移性去势难治性前列腺患者的卡巴他赛间接治疗比较, objectType=article, longId=135900, objectId=e93a135900b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93a135900b3, replyNumber=0, likeNumber=78, createdTime=2018-04-21, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93a135900b3, moduleTitle=PLoS One：转移性去势难治性前列腺患者的卡巴他赛间接治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93a135900b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528459, encodeId=832715284594f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？, objectType=article, longId=134944, objectId=1e5a1349449d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e5a1349449d, replyNumber=0, likeNumber=65, createdTime=2018-04-13, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e5a1349449d, moduleTitle=Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e5a1349449d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528458, encodeId=30841528458c8, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后, objectType=article, longId=134263, objectId=786e13426328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=786e13426328, replyNumber=0, likeNumber=63, createdTime=2018-04-06, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=786e13426328, moduleTitle=NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=786e13426328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528457, encodeId=c2df152845ebb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Oncogene：孤儿核受体TLX在去势难治性前列腺癌中能够导致雄激素不敏感, objectType=article, longId=133965, objectId=aa43133965b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa43133965b6, replyNumber=0, likeNumber=31, createdTime=2018-04-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa43133965b6, moduleTitle=Oncogene：孤儿核受体TLX在去势难治性前列腺癌中能够导致雄激素不敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa43133965b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528456, encodeId=90ff152845643, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验, objectType=article, longId=133936, objectId=36181339363b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36181339363b, replyNumber=0, likeNumber=79, createdTime=2018-04-02, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36181339363b, moduleTitle=初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36181339363b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528455, encodeId=3a54152845560, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=NEJM： Venetoclax-Rituximab用于复发难治性慢性淋巴细胞白血病, objectType=article, longId=133114, objectId=c4d3133114d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4d3133114d2, replyNumber=0, likeNumber=55, createdTime=2018-03-24, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4d3133114d2, moduleTitle=NEJM： Venetoclax-Rituximab用于复发难治性慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4d3133114d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528454, encodeId=167415284542b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet haemat：BP1001，Grb2的反义寡核苷酸，用于难治性/复发性恶性血液病的疗效和安全性评估, objectType=article, longId=132551, objectId=bc0a132551d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc0a132551d5, replyNumber=0, likeNumber=28, createdTime=2018-03-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc0a132551d5, moduleTitle=Lancet haemat：BP1001，Grb2的反义寡核苷酸，用于难治性/复发性恶性血液病的疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc0a132551d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528453, encodeId=d7971528453d9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=中山大学中山眼科中心：倾尽全力攻克难治性眼底病，让患者重获光明, objectType=article, longId=131653, objectId=cff213165391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cff213165391, replyNumber=0, likeNumber=68, createdTime=2018-03-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cff213165391, moduleTitle=中山大学中山眼科中心：倾尽全力攻克难治性眼底病，让患者重获光明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff213165391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528452, encodeId=d1f21528452be, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood：复发性/难治性霍奇金淋巴瘤的移植治疗管理, objectType=article, longId=131455, objectId=33fe131455e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33fe131455e9, replyNumber=0, likeNumber=67, createdTime=2018-03-06, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33fe131455e9, moduleTitle=Blood：复发性/难治性霍奇金淋巴瘤的移植治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33fe131455e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528451, encodeId=db99152845151, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, objectType=article, longId=130441, objectId=33e2130441cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e2130441cc, replyNumber=0, likeNumber=67, createdTime=2018-02-25, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e2130441cc, moduleTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e2130441cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528450, encodeId=ca4a152845065, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Hematol Oncol：难治性/复发性MCL患者：来那度胺是良药吗？, objectType=article, longId=130439, objectId=5dcb130439ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcb130439ce, replyNumber=0, likeNumber=58, createdTime=2018-02-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcb130439ce, moduleTitle=J Hematol Oncol：难治性/复发性MCL患者：来那度胺是良药吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcb130439ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528449, encodeId=a692152844994, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=2018 ILROG指南：复发/难治性弥漫性大B细胞淋巴瘤患者放射治疗的作用, objectType=article, longId=129689, objectId=eb3012968908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3012968908, replyNumber=0, likeNumber=47, createdTime=2018-02-13, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3012968908, moduleTitle=2018 ILROG指南：复发/难治性弥漫性大B细胞淋巴瘤患者放射治疗的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3012968908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528448, encodeId=de431528448b7, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Nucl Med：林岩松团队向碘难治性甲状腺癌发起挑战, objectType=article, longId=128659, objectId=02561286598f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02561286598f, replyNumber=0, likeNumber=82, createdTime=2018-02-04, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02561286598f, moduleTitle=J Nucl Med：林岩松团队向碘难治性甲状腺癌发起挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02561286598f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528447, encodeId=8ec4152844ea4, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood：依鲁替尼联合R-ICE用于复发性/难治性弥漫性大B细胞淋巴瘤患者的I期研究结果, objectType=article, longId=128600, objectId=c14a1286000a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c14a1286000a, replyNumber=0, likeNumber=59, createdTime=2018-02-04, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c14a1286000a, moduleTitle=Blood：依鲁替尼联合R-ICE用于复发性/难治性弥漫性大B细胞淋巴瘤患者的I期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c14a1286000a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528446, encodeId=c9a915284460a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=NEJM：Kymriahc治疗儿童和青年复发或难治性B细胞急性淋巴细胞白血病, objectType=article, longId=128476, objectId=1e4c1284e6be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4c1284e6be, replyNumber=0, likeNumber=79, createdTime=2018-02-02, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4c1284e6be, moduleTitle=NEJM：Kymriahc治疗儿童和青年复发或难治性B细胞急性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4c1284e6be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528445, encodeId=f27715284455f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=难治性眼底病在我国实现微创治疗突破, objectType=article, longId=128440, objectId=46b312844013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46b312844013, replyNumber=0, likeNumber=63, createdTime=2018-02-02, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46b312844013, moduleTitle=难治性眼底病在我国实现微创治疗突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46b312844013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528444, encodeId=a97f1528444d2, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Prostate cancer P D：α (1,6)岩藻糖转移酶在去势难治性前列腺癌细胞中的过表达分析, objectType=article, longId=128400, objectId=954712840073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954712840073, replyNumber=0, likeNumber=61, createdTime=2018-02-02, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954712840073, moduleTitle=Prostate cancer P D：α (1,6)岩藻糖转移酶在去势难治性前列腺癌细胞中的过表达分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954712840073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528443, encodeId=82871528443a5, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=JAMA Neurol：及时的一线治疗可降低难治性惊厥性癫痫患者严重不良预后风险, objectType=article, longId=127382, objectId=5ca212e3822f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ca212e3822f, replyNumber=0, likeNumber=60, createdTime=2018-01-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ca212e3822f, moduleTitle=JAMA Neurol：及时的一线治疗可降低难治性惊厥性癫痫患者严重不良预后风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ca212e3822f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

Leukemia：复发/难治性MM治疗进展：新药、单克隆抗体及免疫治疗

2018-04-23

freve (审核中...)

前往app查看评论内容

#难治性#

Prostate：在非转移性去势难治性前列腺癌患者中，早期雄激素受体靶向药物治疗能够提高总生存

2018-04-22

freve (审核中...)

前往app查看评论内容

#难治性#

PLoS One：转移性去势难治性前列腺患者的卡巴他赛间接治疗比较

2018-04-21

freve (审核中...)

前往app查看评论内容

#难治性#

Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？

2018-04-13

freve (审核中...)

前往app查看评论内容

#难治性#

NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后

2018-04-06

freve (审核中...)

前往app查看评论内容

#难治性#

Oncogene：孤儿核受体TLX在去势难治性前列腺癌中能够导致雄激素不敏感

2018-04-03

freve (审核中...)

前往app查看评论内容

#难治性#

初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验

2018-04-02

freve (审核中...)

前往app查看评论内容

#难治性#

NEJM： Venetoclax-Rituximab用于复发难治性慢性淋巴细胞白血病

2018-03-24

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet haemat：BP1001，Grb2的反义寡核苷酸，用于难治性/复发性恶性血液病的疗效和安全性评估

2018-03-17

freve (审核中...)

前往app查看评论内容

#难治性#

中山大学中山眼科中心：倾尽全力攻克难治性眼底病，让患者重获光明

2018-03-08

freve (审核中...)

前往app查看评论内容

#难治性#

Blood：复发性/难治性霍奇金淋巴瘤的移植治疗管理

2018-03-06

医者仁心 (审核中...)

前往app查看评论内容

#难治性#

Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？

2018-02-25

freve (审核中...)

前往app查看评论内容

#难治性#

J Hematol Oncol：难治性/复发性MCL患者：来那度胺是良药吗？

2018-02-25

freve (审核中...)

前往app查看评论内容

#难治性#

2018 ILROG指南：复发/难治性弥漫性大B细胞淋巴瘤患者放射治疗的作用

2018-02-13

freve (审核中...)

前往app查看评论内容

#难治性#

J Nucl Med：林岩松团队向碘难治性甲状腺癌发起挑战

2018-02-04

freve (审核中...)

前往app查看评论内容

#难治性#

Blood：依鲁替尼联合R-ICE用于复发性/难治性弥漫性大B细胞淋巴瘤患者的I期研究结果

2018-02-04

freve (审核中...)

前往app查看评论内容

#难治性#

NEJM：Kymriahc治疗儿童和青年复发或难治性B细胞急性淋巴细胞白血病

2018-02-02

freve (审核中...)

前往app查看评论内容

#难治性#

难治性眼底病在我国实现微创治疗突破

2018-02-02

freve (审核中...)

前往app查看评论内容

#难治性#

Prostate cancer P D：α (1,6)岩藻糖转移酶在去势难治性前列腺癌细胞中的过表达分析

2018-02-02

freve (审核中...)

前往app查看评论内容

#难治性#

JAMA Neurol：及时的一线治疗可降低难治性惊厥性癫痫患者严重不良预后风险

2018-01-25

科室
- - 订阅+
  - 更多科室
工具
服务